CARSON CITY, Nev. - BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company, has announced new clinical data regarding its drug candidate bezisterim at the 11th Aging Research and Drug Discovery (NASDAQ:WBD) Meeting in Copenhagen, Denmark. The data suggests bezisterim may influence the biological aging process and chronic inflammation associated with aging-related diseases.
The study presented by BioVie's Senior Vice President, Christopher L. Reading, indicates that patients treated with bezisterim showed a two to four-year biological age deceleration advantage over those receiving a placebo. This was measured using a series of "biological clocks," which assess age based on DNA methylation patterns.
DNA methylation, a process that occurs naturally with age, can affect gene function and is linked to many age-related diseases. Bezisterim appears to modulate the methylation of specific proinflammatory genes, potentially aiding in the transition from a proinflammatory state to an anti-inflammatory state in macrophages, which are key cells in the body's immune response.
The drug is associated with a 1.5 to 2.3-fold enrichment on gene control in pathways linked to neurodegenerative disorders such as Alzheimer's and Parkinson's disease, as well as biological processes like apoptosis and TNF signaling.
BioVie's President and CEO, Cuong Do, emphasized the significance of the findings, stating that the data provides a deep understanding of how bezisterim may work at the gene level to reduce inflammation and impact disease.
Bezisterim is being investigated for its potential in treating Alzheimer's disease (AD) and Parkinson's disease (PD). BioVie has already reported efficacy data from its Phase 3 study on patients with mild-to-moderate AD.
The company also shared results from a Phase 2 trial at the AD/PD™ 2023 International Conference, showing that bezisterim-treated patients experienced improvements in cognition and motor control when used in combination with levodopa for Parkinson's disease.
BioVie's research is ongoing, and the company is in discussions with the FDA regarding Phase 3 clinical testing of another drug candidate for liver disease. The information presented is based on a press release statement from BioVie Inc.
In other recent news, BioVie Inc. has seen significant developments. The pharmaceutical company has successfully regained compliance with Nasdaq's minimum bid price requirement, according to a recent filing with the Securities and Exchange Commission. This follows a period of uncertainty for the company's investors and signifies a positive step towards stabilizing its market position.
In addition, BioVie has completed a 1-for-10 reverse stock split of its Class A common stock, a corporate action approved by the company's shareholders. This move is intended to consolidate shares, a common strategy companies use to meet stock exchange listing requirements or improve the marketability of their stock.
Furthermore, the company announced the resignation of director Steve Gorlin, marking a significant change in the firm's leadership structure. BioVie also reported substantial progress in its Phase 2a trial of bezisterim for Parkinson's Disease treatment. The trial data revealed that bezisterim, used alongside levodopa/carbidopa, led to considerable improvements in both motor and non-motor symptoms compared to a placebo. These developments underscore BioVie's ongoing commitment to pharmaceutical innovation and corporate evolution.
InvestingPro Insights
As BioVie Inc. (NASDAQ: BIVI) continues to develop promising treatments for aging-related diseases, the company's financial health and stock performance provide a broader context for investors. Despite the potential of its drug candidate bezisterim, BioVie's stock has faced significant challenges recently. According to InvestingPro data, the company's market capitalization stands at a modest $18.34 million, underscoring its small-cap status in the biopharmaceutical industry.
An InvestingPro Tip highlights that BioVie's stock has taken a considerable hit over the past week, with a price total return of -10.18%. This trend extends over the last month and six months, with returns of -36.17% and -76.38%, respectively, reflecting a period of volatility and investor caution. The company's price is currently at 5.15% of its 52-week high, indicating a significant drop from previous valuations.
With a negative price-to-earnings (P/E) ratio of -0.31 and an adjusted P/E ratio for the last twelve months as of Q3 2024 at -0.49, the financial metrics suggest that profitability is a concern, as analysts do not anticipate BioVie will be profitable this year. In line with this, the company does not pay a dividend to shareholders, which can be a consideration for those seeking income-generating investments.
However, it's not all challenging news. BioVie holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations, indicating a degree of financial stability that may support its ongoing research and development efforts. For investors interested in a more comprehensive analysis, there are additional InvestingPro Tips available, providing deeper insights into BioVie's financial health and market performance.
For those looking to explore further, InvestingPro offers a total of 10 tips on BioVie, which can be found at https://www.investing.com/pro/BIVI. These tips could provide valuable guidance for investors considering BioVie as part of their investment portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.